Neoadjuvant Chemotherapy Beneficial in High-Risk UTUC
Findings of a phase 2 trial support the use of neoadjuvant chemotherapy as a standard of care, according to investigators.
Findings of a phase 2 trial support the use of neoadjuvant chemotherapy as a standard of care, according to investigators.
Intensified ADT with apalutamide, with or without abiraterone plus prednisone, for 52 weeks prolonged PSA progression-free survival compared with ADT alone among men with high-risk biochemically recurrent prostate cancer following radical prostatectomy.
In a recent bulletin, the federal Office for Civil Rights suggests steps that practices can take to protect patient data.
A family history of prostate cancer appears to boost awareness of the disease, which in turn prompts men to seek screening, according to investigators.
How the retail giant will use the sensitive medical data it collects is among the concerns.
Physician retirements and challenges in recruiting and retaining staff are among the reasons medical practices are struggling with staff shortages.
Annual pay, growth potential, cost of living are among the important considerations.
An international panel weighed in on management controversies in intermediate- and high-risk and locally advanced prostate cancer.
The FBI and other federal agencies have issued warnings about a ransomware and data extortion group called the Daixin Team.
Study findings could help inform older patients who opt to start dialysis on what to expect regarding development of their symptom burden, according to investigators.